Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Omega ; 8(12): 11310-11317, 2023 Mar 28.
Article in English | MEDLINE | ID: mdl-37008087

ABSTRACT

In this study, the results and experimental data under static conditions are verified based on a calculation method. The deviation is controlled within 10%, which verifies the reliability of the experimental data. It is found that pitching has the most obvious influence on heat transfer. Through an analysis of the heat transfer coefficient on the shell side and the friction pressure drop along the path, the variation under rocking conditions is obtained.

2.
Mol Cancer Ther ; 18(1): 100-111, 2019 01.
Article in English | MEDLINE | ID: mdl-30361332

ABSTRACT

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediated activation; however, the outcomes in patients are not so promising. Increasing evidence show that MET has kinase-independent effects on tumorigenesis and dissemination, which explains the low efficacy in kinase inhibition-based strategy. VHH is the recombinant variable region of Camelid heavy-chain antibody. As a nanoscale antigen-binding unit, VHH has become an appealing drug candidate in cancer therapy. In our study, we choose a novel strategy to construct an anti-MET VHH pool against the whole ecto-domain of MET. Comparing to monoclonal antibody or single VHH, the anti-MET VHH pool strongly promotes MET degradation through Clathrin-dependent endo-lysosomal pathway. Thus, the anti-MET VHH pool not only blocks kinase activity of MET, but also reduces protein level of MET. As a consequence, anti-MET VHH pool dramatically suppresses cancer cell proliferation, viability, and colony formation in vitro, and inhibits tumorigenesis and growth in mice. Taken together, VHH pool-based strategy greatly improves MET-targeted therapeutic effects on cancer.


Subject(s)
Drug Resistance, Neoplasm/drug effects , Neoplasms/drug therapy , Proto-Oncogene Proteins c-met/chemistry , Single-Domain Antibodies/administration & dosage , Animals , Camelidae , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Hep G2 Cells , Humans , Male , Mice , NIH 3T3 Cells , Neoplasms/metabolism , Proteolysis , Proto-Oncogene Proteins c-met/metabolism , Single-Domain Antibodies/pharmacology , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...